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ABSTRACT 
Introduction: BKV nephropathy (BKN) causes kidney graft loss, whose specifi c diagnosis is invasive 
and might be predicted by the early detection of active viral infection. Objective: Determine the 
BKV-infection prevalence in late kidney graft dysfunction by urinary decoy cell (DC) and viral DNA 
detection in urine (viruria) and blood (viremia; active infection). Methods: Kidney recipients with 
>1 month follow-up and creatinine >1.5 mg/dL and/or recent increasing >20% (n = 120) had their 
urine and blood tested for BKV by semi-nested PCR, DC searching, and graft biopsy. PCR-positive 
patients were classifi ed as 1+, 2+, 3+. DC, viruria and viremia prevalence, sensitivity, specifi city, and 
likelihood ratio (LR) were determined (Table 2x2). Diagnosis effi cacy of DC and viruria were com-
pared to viremia. Results: DC prevalence was 25%, viruria 61.7%, and viremia 42.5%. Positive and 
negative patients in each test had similar clinical, immunossupressive, and histopathological char-
acteristics. There was no case of viremia with chronic allograft nephropathy and, under treatment 
with sirolimus, patients had a lower viruria prevalence (p = 0.043). Intense viruria was the single 
predictive test for active infection (3+; LR = 2.8).1,6-4,9 Conclusion: DC, BKV-viruria and -viremia are 
commun fi ndings under late kidney graft dysfunction. Viremia could only be predicted by intense 
viruria. These results should be considered under the context of BKN confi rmation.
Keywords: BK virus, decoy cells, kidney transplantation, PCR, viremia, viruria.
[Braz J Infect Dis 2010;14(2):170-174]©Elsevier Editora Ltda.
INTRODUCTION
Opportunistic infections are a major cause of 
morbidity after transplantation. Such fact has 
stimulated studies toward virus epidemiology, 
biology, and pathogenic effects among this 
high risk population.1 BK virus (BKV), a mem-
ber of the Polyomavirus family, is a common 
viral infection, as cytomegalovirus, which is as-
sociated with high risk of renal disorder after 
kidney transplantation.2
The primary infection occurs during early 
childhood, and becomes latent in the kidneys. 
As soon as the immunosuppression starts at the 
time of transplantation, the virus can reactivate 
and develop a clinically relevant disease, which 
is manifested as tubulointersticial nephritis 
(known as BKV nephropathy [BKN] and/or 
ureteral stenosis).3-6 
BKN has been associated with graft dys-
function in 3% to 14% of kidney recipients, 
leading to graft failure in up to 67% of the 
cases.2,7,8 Specifi c diagnosis of BKN depends on 
the pathological tissue patterns on the graft bi-
opsy specimen, which can be confounded with 
cellular rejection mainly when both patholo-
gies coexist. Thus, BKN diagnosis, based ex-
clusively on the pathological criteria, might be 
diffi cult.4-11
This study was designed to investigate the 
prevalence of BKV infection among patients 
under late kidney graft dysfunction. It com-
bines three non-invasive methodologies: uri-
nary cytology (looking for decoy cells; DC), 
viruria (urinary viral DNA), and viremia (ac-
tive infection; blood viral DNA), and takes into 
consideration the importance of an early diag-
nosis and the need of graft biopsy invasiveness 
to defi ne a suspicion of BKN. 
PATIENTS AND METHODS
Patients
Kidney transplant recipients (n = 120), from 
living or deceased donors, with serum creati-
nine levels above 1.5 mg/dL or recent increase 
of > 20%2,12 were allocated during 1 year of 
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outpatient follow-up. After signing an informed consent, 
previously approved by the local Ethic Committee, patients 
performed a graft biopsy, and urine and blood samples were 
collected. Patients who refuse to participate, those younger 
than 18 years old or less than 1 month of post-transplant 
follow-up, and patients with a known and reversible cause 
for graft dysfunction were excluded from the study.
Urinary cytology
Papanicolau standard staining was performed in urinary 
sediment. DC were recognized for their typical round-glass 
intranuclear inclusions with a peripheral of hyperchromatic 
chromatin.13-15 
Molecular biology
DNA extraction
Pellet urinary sediment was used for DNA extraction fol-
lowing the protocol previously published by Takayama et 
al.4 Blood samples collected in EDTA anticoagulant were 
submitted to DNA extraction using a commercial kit (Pure-
LinkGenomic, Invitrogen, USA). 
Polymerase Chain Reaction (PCR)
Semi-nested PCR was performed in order to detect the BKV 
DNA, as validated by Nickeleit et al.13 The outer primer pair, 
5’ AAGTCTTTAGGGTCTTCTAC 3’ and 5’ GTGCCAAC-
CTATGGAACAGA 3’, was used to generate a 176-bp, a com-
mon amplicon among Polyomaviridae memberships. It was 
used the primer 5’ AAGTCTTTAGGGTCTTCTAC 3’ with 5’ 
GAGTCCTGGTGGAGTTCC 3’ in order to obtain a 149-bp 
fragment, a specifi c BKV-region.16
A spectrophotometer, using a 260 nm length wave (Bio 
Photometer, Eppendorf, Germany), was used to standardize 
the total DNA content at 0.5 and 0.1 µg in blood and urine 
samples, respectively, for PCR reaction. Amplifi cation steps 
were performed from a 25 µl reaction-mixture containing 
1.5 mM MgCl2, 0.5 µM of each primer, dNTPs 200 µM and 
2.5 U of Taq polymerase (Invitrogen, Brazil).
The reaction program consisted of 5 minute-denatura-
tion at 94º C and were followed by 35 cycles of denaturation 
at 94º C during 1 minute, annealing at 56º C for 1 minute and 
extension at 72º C for 5 minutes. A fi nal extension at 72º C 
for 10 minutes was added. 
Free DNA samples were analyzed as negative controls, 
and DNA obtained from a known BKV-positive patient was 
used as positive control in each test. All negative tests had 
their content and quality DNA certifi ed by amplifi cation us-
ing a primer for β-globine detection. 
Semi-quantitative PCR analysis
The amplifi ed regions were detected in agarose gel 2.5% 
stained with ethidium bromide. The amplifi ed urine and 
blood products were qualifi ed as 1+, 2+, 3+, according to 
that observed at the transilluminator, corresponding, re-
spectively, to weak, intermediate, and strong intensity of 
amplifi cation.
Histology 
All biopsies were classifi ed according to Banff criteria 1997 
for kidney graft pathologies defi nition.17 
Statistical analysis
Data were expressed as percentage, mean and standard 
deviation or median and range. Comparisons of age and 
creatinine levels were performed by Student’s t-test. Other 
characteristics and risk factors of patients were analyzed by 
Chi-squared or Fisher’s exact test, as indicated. Sensitivity 
and specifi city were described as percentage and likelihood 
ratio (LR), and were calculated by using Table 2x2. For study 
purposes, DC and viruria values were compared with the 
presence of BKV DNA in peripheral blood. The software 
Statistical Package for Social Sciences 14.0 was used for all 
statistical analysis, being signifi cant p values ≤ 0.05 and con-
fi dence intervals 95%.
RESULTS
Among the 120 kidney recipients under late graft dysfunc-
tion, the prevalence of DC was 25.0% (95% CI: 17.5-33.7), 
viruria 61.7% (95% CI: 52.4-70.4), and viremia 42.5% (95% 
CI: 33.5-51.9). Serum creatinine 2.3 mg/dL (0.8-8.5 mg/dL), 
and median follow-up was 1.6 years.
There was predominance of male gender 60.8% (n = 73/120) 
and 56.7% were recipients from deceased donors (n = 68/120). 
Patients receiving a second or third allograft represented 
10.0% of the sample (12/120), and there was 16.7% (17/102) 
of anti-HLA class I pre-sensitized patients. Induction with 
immunosuppressants had been used by 15.0% (18/120) of 
them at the time of transplantation, and current prophy-
latic immunosuppressive scheme was a combination of 
the following drugs: prednisone (n = 103; 94.2%), mofetil 
mycofenolate (n = 80; 66.7%), tacrolimus (n = 60; 50.0%), 
cyclosporine (n = 55; 45.8%), azatioprine (n = 24; 20.0%), 
and sirolimus (n = 14; 11.7%). General characteristics are 
presented in Table 1.
Clinical characteristics, pre-transplant immunologi-
cal risk, current immunosuppressive protocol, and kidney 
histopathology fi ndings were similar among negative and 
positive patients, taking into consideration each laboratory 
test performed. An exception was the higher rate of patients 
treated with sirolimus, showing a lower prevalence of posi-
tive urine BKV-DNA detection (p = 0.043). Another differ-
ence was observed among patients with current diagnosis of 
chronic allograft nephropathy (CAN). In this group, no case 
of BKV-DNA in peripheral blood p = 0.020) was detected.
Table 2 describes the comparison of diagnostic effi cacy 
of urinary cytopathic effect (DC) and BKV-viruria with 
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Table 1. Clinical characteristics of kidney transplant recipients under late graft dysfunction 
studied for BKV infection
Recipient’s Characteristics*     n (%)
Male gender 73 60.8
Re-transplant 12 10.0
Pre-sensitization** 17 16.7
Deceased donor 68 56.7
Induction therapy*** 18 15.0
Previous CMV disease 34 28.3
Previous AR 19 15.2
Previous CAN 14 11.7
CyA-Aza-Pred 17 14.2
CyA-MMF-Pred 31 25.8
FK-MMF-Pred 44 36.7
FK-Sirol-Pred 10 8.3
* n = 120
** patients evaluated for anti-HLA antibodies before transplantation (n = 102)
*** basiliximab
CMV: cytomegalovirus
AR: acute rejection defined by biopsy
CAN: chronic allograft nephropathy 
CyA: cyclosporine
Aza: azatioprine
Pred: prednisone
MMF: mofetil mycofenolate
FK: tacrolimus
Sirol: sirolimus.
Table 2. Comparison of diagnostic efficacy of urinary cytopatic effect (DC) and BKV-viruria 
with BKV-viremia in kidney transplant recipients under late graft dysfunction
 BKV viremia +  BKV viremia -   LR 95% CI Post test
 n (%) n (%)    probability (%)
Urine BKV PCR (1)
Negative 11 (21.6)  35(50.7)  0.43 0.24–0.75 24.1 
1+ (2) 5 (9.8)  14 (20.3) 0.48 0.19–1.26 26.2 
2+ (2) 8 (15.7) 7 (10.1) 1.55 0.60–3.99 53.4 
3+ (2) 27 (52.9) 13 (18.8) 2.81 1.61–4.89 67.5 
Decoy Cells (DC) (3)
Negative 35 (68.6)  55 (79.7) 0.86 0.69–1.07 38.9 
Positive 16 (31.4) 14 (20.3 1.55 0.83–2.87 53.3 
Viruria: urine BKV PCR
Viremia: peripheral blood BKV PCR
Pb: peripheral blood
LR: likelihood ratio
CI: confidence interval
PCR: polymerase chain reaction
(1) Sensitivity: 78.4% (95% CI: 64.7-88.7), Specificity: 50.7% (95% CI: 38.4-63.0)
(2) Intensity of amplification: 1 (weak); 2 (intermediate); 3 (strong)
(3) Sensitivity: 31.4% (95% CI: 19.1-45.9), Specificity: 79.7% (95% CI: 68.3-88.4)
Prevalence of BKV in peripheral blood: 42.5% (95% CI: 33.5-51.9).
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BKV-viremia among the studied patients. In this study, 
strong urine BKV amplifi cation (3+) achieved a LR of 2.8 
predicting viremia, indicating a post test probability (PTP) 
of 67.5% (95% CI: 1.61-4.89). The effi cacy of DC for viremia 
prediction was not confi rmed when taking into account CI 
achieved and its ability to improve the pre-test odds.
DISCUSSION
Early BKN diagnosis and reduction of the immuno-
suppressive therapy are the major strategies to improve 
graft survival and stabilize serum creatinine after kidney 
transplantation.18-20
The most important tool to establish this diagnosis de-
pends on the graft pathological pattern, but the multifocal 
appearance in the parenchyma, the heterogeneous nature 
of viral inclusions, and the immunohistochemical fi ndings 
compromise the accuracy of the anatomopathological BKN 
diagnosis.2,21,22 As a consequence, complementary and non-
invasive tests, such as DC into the urinary sediment, viruria 
and viremia detection, and renal function follow up,9,19,22 can 
be important to early predict and manage nephropathy.
Among the population studied, the prevalence of DC, 
viruria, and viremia using these complementary tests were, 
respectively, 25%, 62%, and 42%. Besides these high fre-
quencies of BKV infection signals,5,21,23-26 this study also con-
fi rms the previous evidence of no clinical or histopathologi-
cal characteristics associated with BKV infection.2,24,26,27,28
In agreement with others,26-28 there was no association 
with acute rejection or with its treatment. On the other 
hand, reinforcing the importance of an early diagnosis, no 
case of viremia among patients with current CAN highlights 
their probable severe renal damage hindering the viral repli-
cation. Another interesting fi nding was the lower prevalence 
of viruria among patients under treatment with sirolimus. 
This drug acts as an anti-proliferative agent and has been 
suggested as an alternative treatment for viral replication 
control in established BKV disease.30,31
Molecular detection of polioviruses has been considered 
as a gold-standard, and its effi cacy has been confi rmed by a 
variety of studies.2,13,24,32 Nowadays, regarding the countless 
different molecular techniques available for Polyomavirus 
detection,16,32 quantitative PCR with viral load defi nition is the 
most sensitive and specifi c approach. Urinary DC, considered 
as having the higher negative predictive value up to now,5,24 has 
been substituted by urine PCR. DC has a signifi cant sensitiv-
ity for BKN detection, but PCR is up to 4 times more sensitive 
for viruria monitoring in asymptomatic patients, and also has 
the stability advantage upon the DC for that.32,33 However, not 
taking viruria into account, as suggested by some authors,34,35 
can be contested.36 Despite the controversy, the uncommon 
occurrence of viruria or viremia among health people are due 
to JCV, a less uropathogenic agent.24,28,35,37-41 Hence, BKV viru-
ria itself probably have clinical relevance. 
The present study showed the urinary high BKV ampli-
fi cation intensity as the single test able to predict viremia 
occurrence (3+; LR = 2.8; 95% CI: 1.6-4.9). In this group, 
the presence of DC did not achieve clinical signifi cance for 
viremia prediction (LR = 1.55; 95% CI: 0.8-2.9). Such fi nd-
ing becomes even more relevant due to the fact that viremia 
only occurs under active replication, not being observed 
during latent periods.15,42 BKV-PCR can be clinically used 
as a non-invasive test in order to identify kidney transplant 
recipients under risk or suspicion of BKN. Nickeleit and 
coworkers demonstrated that the viremia detection by semi-
nested PCR can achieve up to 100% sensitivity and 88% 
specifi city for nephropathy diagnosis.13 Quantitative-PCR 
has already defi ned some viral load cut-offs correlated with 
BKN risk: > 1.6E+04 copies/mL in plasma; > 2.5E+07 cop-
ies/mL in urine; > 7700 copies/mL in total blood.24,43 
There is a direct correlation between viremia load, graft 
dysfunction degree, severity of histological BKN tissue pat-
terns, and number of infected renal cells in histological 
slide.37 Such correlation suggests that viremia occurs mainly, 
if not entirely, from the viral replication started in the kid-
ney. This is the reason why the amount of viremia is more 
predictive of BKN than the viruria.16,24,44,45 
Finally, viremia is a late BKV-infection event, associat-
ed with graft dysfunction and works as a marker for BKN 
development.28 It occurs 16 to 33 weeks previously to the 
establishment of BKN,13 and invariably appears later than 
viruria.36 Thus, an intense BKV-viruria predicts viremia, and 
probably BKN.
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